

Favorable radiation field decrease in gastric marginal zone lymphoma: experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)

Gabriele Reinartz, Regina P. Pyra, Georg Lenz, Rüdiger Liersch, Georg Stüben, Oliver Micke, Kay Willborn, Clemens F. Hess, Andreas Probst, Rainer Fietkau, Ralf Jany, Jürgen Schultze, Christian Rübe, Carsten Hirt, Wolfgang Fischbach, Martin Bentz, Severin Daum, Christiane Pott, Markus Tiemann, Peter Möller, Andreas Neubauer, Martin Wilhelm, Normann Willich, Wolfgang E. Berdel, Hans T. Eich

Angaben zur Veröffentlichung / Publication details:

Reinartz, Gabriele, Regina P. Pyra, Georg Lenz, Rüdiger Liersch, Georg Stüben, Oliver Micke, Kay Willborn, et al. 2019. "Favorable radiation field decrease in gastric marginal zone lymphoma: experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)." *Strahlentherapie und Onkologie* 195 (6): 544–57.
<https://doi.org/10.1007/s00066-019-01446-5>.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under these conditions:

Deutsches Urheberrecht


Weitere Informationen finden Sie unter: / For more information see:

<https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publiz/>



Favorable radiation field decrease in gastric marginal zone lymphoma

Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)

Gabriele Reinartz¹  · Regina P. Pyra¹ · Georg Lenz² · Rüdiger Liersch² · Georg Stüben³ · Oliver Micke⁴ · Kay Willborn⁵ · Clemens F. Hess⁶ · Andreas Probst⁷ · Rainer Fietkau⁸ · Ralf Jany⁹ · Jürgen Schultze¹⁰ · Christian Rube¹¹ · Carsten Hirt¹² · Wolfgang Fischbach¹³ · Martin Bentz¹⁴ · Severin Daum¹⁵ · Christiane Pott¹⁶ · Markus Tiemann¹⁷ · Peter Möller¹⁸ · Andreas Neubauer¹⁹ · Martin Wilhelm²⁰ · Normann Willich¹ · Wolfgang E. Berdel² · Hans T. Eich¹

Abstract

Purpose Long-term impact of stage-adapted field reduction in a large cohort of gastric marginal zone lymphoma (gMZL) patients treated conservatively with curative radiation therapy (RT).

Patients and methods Prospective analysis of paper records of 290 patients with stage IE–IIIe gMZL, treated in 78 radiotherapeutic institutions in Germany from 1992–2013. Stage-adapted radiation fields decreased from extended field (EF) to involved field (IF) over the course of three consecutive prospective trials of the German Study Group on Gastrointestinal Lymphoma (DSGL). Treatment results were compared between the three cohorts.

✉ Gabriele Reinartz
gabriele.reinartz@ukmuenster.de

¹ Department of Radiation Oncology, University Hospital of Münster, Building A1, Albert Schweitzer Campus 1, 48149 Münster, Germany

² Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Münster, Münster, Germany

³ Department of Radiation Oncology, Hospital Augsburg, Augsburg, Germany

⁴ Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Bielefeld, Germany

⁵ Department of Radiotherapy and Radiation Oncology, Pius Hospital Oldenburg, Oldenburg, Germany

⁶ Department of Radiation Oncology, University Hospital of Göttingen, Göttingen, Germany

⁷ Department of Gastroenterology, Central Hospital, Augsburg, Germany

⁸ Department of Radiation Oncology, University of Erlangen, Erlangen, Germany

⁹ Department of Radiation Oncology, Saint Marien Hospital, Hamm, Germany

¹⁰ Department of Radiation Oncology, University of Schleswig-Holstein, Kiel, Germany

¹¹ Department of Radiation Oncology, University of Saarland, Homburg, Germany

¹² Department of Medical Oncology, University of Greifswald, Greifswald, Germany

¹³ Department of Gastroenterology and Oncology, Hospital of Aschaffenburg, Aschaffenburg, Germany

¹⁴ Department of Medical Oncology, Municipal Hospital of Karlsruhe, Karlsruhe, Germany

¹⁵ Department of Gastroenterology, University Charité, Berlin, Germany

¹⁶ Department of Medical Oncology, University of Schleswig-Holstein, Kiel, Germany

¹⁷ Institute for Hematopathology Hamburg, Hamburg, Germany

¹⁸ Department of Pathology, University of Ulm, Ulm, Germany

¹⁹ Department of Medical Oncology, University of Marburg, Marburg, Germany

²⁰ Department of Medical Oncology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany

Results Overall collective with median age of 60 years, slight male predominance (m:f=1.1:1) and ratio of disease stage I:stage II=2.1:1. Median follow-up 6.4 years in total: 13.0 years in the first gastrointestinal study (GIT 1992), 8.2 years in the second (GIT 1996) and 4.7 years in the third study (DSGL 01/2003). Stage-adapted radiation field decrease together with further technological development led to reduced relative frequencies of acute/chronic adverse effects and until now was accompanied by lower disease recurrence. The third study design with smallest field size (IF in stage I, locoregional EF in stage II) achieved the best survival outcome at the 5-year follow-up (overall survival 92.7%, event-free survival 89.5% and lymphoma-specific survival 100.0%). Disease relapse observed in 10 patients. Cumulative incidence of disease-specific death was 1.7% of the followed patients. Primary disease stage associated with lymphoma-specific survival.

Conclusion Stage-adapted reduction towards IF in gMZL resulted in favorable adverse effects, local control and survival rates. These results support further decreases in modern RT of gMZL.

Keywords Indolent gastric lymphoma · Non-Hodgkin lymphoma · Extended field · Involved field · Radiation therapy

Erfolgreiche Strahlenfeldverkleinerung bei gastralem Marginalzonenlymphom

Erfahrungen der Deutschen Studiengruppe Gastrointestinale Lymphome (DSGL)

Zusammenfassung

Zielsetzung Langzeiteffekt der stadienadaptierten Strahlenfeldverkleinerung bei kurativer Radiotherapie (RT) in einer großen Kohorte von Patienten mit gastralem Marginalzonenlymphom (gMZL).

Patienten und Methoden Prospektive Analyse der Papierakten von 290 Patienten mit gMZL im Stadium IE–IIE, behandelt in 78 radiotherapeutischen Institutionen in Deutschland von 1992–2013. Stadienadaptierte Strahlenfeldreduktion vom „extended field“ (EF) zum „involved field“ (IF) im Verlauf der drei konsekutiven prospektiven Studien der Deutschen Studiengruppe Gastrointestinale Lymphome (DSGL). Behandlungsergebnisse wurden zwischen den drei Studienkohorten verglichen.

Ergebnisse Gesamtkollektiv mit medianem Alter von 60 Jahren; Geschlechterverhältnis m:w=1,1:1 und Stadienverhältnis I:II=2,1:1. Medianes Follow-up insgesamt 6,4 Jahre: 13,0 Jahre in der ersten gastrointestinalen Studie (GIT 1992), 8,2 Jahre in der zweiten (GIT 1996) und 4,7 Jahre in der dritten Studie (DSGL 01/2003). Die stadienadaptierte Strahlenfeldverkleinerung zusammen mit der technischen Weiterentwicklung führte zu reduzierten relativen Häufigkeiten der akuten/chronischen Nebenwirkungen und ist bislang begleitet von einer niedrigeren Rezidivrate. Das Konzept der dritten Studie mit der kleinsten Feldausdehnung (IF im Stadium I, lokoregionales EF im Stadium II) erreichte die besten Überlebensraten nach einem Follow-up von 5 Jahren (Gesamtüberleben 92,7%, ereignisfreies Überleben 89,5% und lymphomspezifisches Überleben 100,0%). Lymphomrezidive wurden bei 10 Patienten beobachtet. Die kumulative Inzidenz der krankheitsspezifischen Todesrate bei den nachbeobachteten Patienten betrug 1,7%. Das primäre Krankheitsstadium war assoziiert mit dem lymphomspezifischen Überleben.

Schlussfolgerung Die stadienadaptierte Feldverkleinerung zum IF bei gMZL resultiert in günstigen Nebenwirkungen, lokaler Kontrolle und Überlebensraten. Diese Ergebnisse bekräftigen die weitere Deeskalation der modernen RT von gMZL.

Schlüsselwörter Indolentes Magenlymphom · Non-Hodgkin-Lymphom · Extended field · Involved field · Radiotherapie

Introduction

The development of modern radiation techniques over the past 25 years has considerably changed the use of radiation therapy (RT) to treat gastric marginal zone lymphoma (gMZL) [1–8]. Radiotherapy is now a central, well-tolerated treatment option with curative potential in gMZL [9, 10]. In this multi-institution study the details of predominantly single-modality RT used to treat gMZL between 1992 and 2013 were evaluated in the context of three consecutive

prospective gastrointestinal (GIT) study designs: GIT 1992 [11, 12], GIT 1996 [13] and DSGL 01/2003 of the German Study Group on Gastrointestinal Lymphoma (DSGL). Merely stage IIE patients in the first study received RT after prior chemotherapy with six cycles of COP (cyclophosphamide, vincristine and prednisolone) [11]. The reduction of RT volume and its therapeutic tolerability is demonstrated. Additionally, its effects on treatment outcome in terms of tumor control, survival results and relapse patterns during long-term follow-up were investigated.

Patients and methods

Patients

The medical paper records of 290 patients with biopsy-proven stage IE or IIE indolent gMZL, who were treated conservatively at 78 radiotherapeutic institutions in Germany between 1992 and 2013, were analyzed prospectively with the follow-up data closure date of April 9, 2018. All patients received curative RT, primarily as the initial oncologic treatment strategy, but the design of the first study required that stage IIE patients be pretreated with six cycles of COP chemotherapy [11]. The primary pathological diagnosis of gMZL was confirmed by a central histopathological review. Institutional review board approval was obtained for the three studies. Protocols were approved by the ethical board of the physicians' chamber of Westfalia-Lippe and the Westfalian Wilhelms-University of Münster, and by local ethics committees of the other participating centers. Each patient gave written informed consent for the study.

Data compiled included clinical characteristics, ECOG (Eastern Cooperative Oncology Group) performance status, lymphoma stage, treatment, acute and chronic adverse effects, follow-up examinations, disease relapse and location, and salvage treatments. Follow-up assessment was completed through additional reviews of all patient charts.

Treatment strategy

Patients underwent endoscopy and computed tomography staging before treatment. After pathologic confirmation of early stage extranodal gMZL, patients were referred to the radiation oncologist for RT with curative intent if the disease was *Helicobacter pylori* (*H. pylori*) independent. Where testing was positive for *H. pylori* in stage IE gMZL (or stage II1 gMZL in patients aged more than 65 years), RT was the treatment if antibiotic therapy failed, defined as progressive disease or no change. The interval from *H. py-*

lori eradication to RT was at least 12 months in case of no change after eradication therapy. Protocol RT was stratified according to disease stage [11, 13], as extended field (EF), reduced extended field (red. EF), or involved field (IF) with continuously decreasing field size throughout the three cohorts. The dose was 40 Gy in the area of the tumor, 30 Gy in terms of prophylactic extended region. Patients were generally treated with anterior–posterior opposing fields or three-dimensional (3D) conformal RT, whereas in the final study the application of intensity-modulated RT (IMRT) has just been started (Table 1).

Follow-up

Esophagogastroduodenoscopy was used for routine evaluation of potential radiogenic toxicity and initial response 8 weeks after treatment completion [10]. It was repeated along with topographic mapping biopsy, abdominal ultrasound, physical examination, serum and hematology laboratory controls and renal function every 3 months for the first 2–3 years, semi-annually for up to 5 years, and annually thereafter. At each point, disease response was classified as either a complete response, complete response uncertain, partial response, no change, or progressive disease, according to GELA (Groupe d' Etude des Lymphomes de l' Adulte) criteria. Relapse was stated when a new manifestation of lymphoma appeared at least 1 month after the first follow-up where a complete response was proven. Failure in the stomach or in the regional lymph nodes was considered a locoregional failure or relapse, and relapse at any other site was considered a distant failure. An early relapse occurred less than one year/a late relapse at least one year after treatment, respectively [14]. Transformation to aggressive lymphoma was considered to be recurrent disease.

Table 1 Study design and radiation technique in indolent gastric marginal zone lymphoma (gMZL)

	GIT 1992		GIT 1996		DSGL 01/2003		
Stage	IE	IIE	IE	IIE	IE	II1E	II2E
Chemotherapy	–	6xCOP	–	–	–	–	–
Radiation therapy	EF 30 Gy + Boost ad 40 Gy	EF-mediast 30 Gy + Boost ad 40 Gy	Red. EF 30 Gy + Boost ad 40 Gy	EF 30 Gy + Boost ad 40 Gy	IF 40 Gy	Red. EF 30 Gy + Boost ad 40 Gy	EF 30 Gy + Boost ad 40 Gy
AP/PA opposing fields	<i>n</i> = 56 (98.2%)		<i>n</i> = 29 (22.3%)		<i>n</i> = 1 (1.0%)		
3D-CRT	<i>n</i> = 1 (1.8%)		<i>n</i> = 101 (77.7%)		<i>n</i> = 101 (98.0%)		
IMRT	–		–		<i>n</i> = 1 (1.0%)		

COP cyclophosphamide, vincristine, prednisone, EF extended field (whole abdomen with pelvis), EF-mediast (whole abdomen + mediastinum), Red. EF reduced EF (abdomen without pelvis), IF involved field (stomach + perigastric nodes + adjacent paraaortic nodes + proximal duodenum), AP/PA anterior–posterior/posterior–anterior, 3D-CRT three-dimensional conformal radiation therapy, IMRT intensity-modulated radiation therapy

Statistical analysis

Baseline patient characteristics and RT treatment were described using medians and ranges. Categorical data were described using absolute and relative frequencies in contingency tables. Acute and chronic adverse effects were evaluated using contingency tables, and χ^2 was used to compare the severity of adverse effects between the three studies. Study endpoints were event-free survival (EFS), overall survival (OS) and lymphoma-specific survival (LSS). EFS was defined as the time from the first day of curative radiation treatment until the date of progression, relapse at any site, death or final follow-up/OS until death or final follow-up/LSS until death caused by the primary disease or its oncologic treatment, respectively. Survival curves were estimated using Kaplan–Meier methods. Influence of treatments and disease factors were assessed using the log-rank test to compare survival curves. The number and types of relapses after primary treatment were also examined. Statistical analyses were performed using IBM® SPSS® Statistics (Version 25.0) (IBM, Armonk, NY, USA). All calculated *p* values were two-sided descriptive measures. Factors with $p \leq 0.05$ were considered statistically significant.

Results

Median age at diagnosis across all three patient cohorts was 60 years (range 24–84 years) and 68% (197/290) of patients had stage IE disease. The basic characteristics of the all three cohorts together are shown in Table 2. Eastern Cooperative Oncology Group performance status was 0–1 in 94.5% of patients. For staging examinations, each patient underwent a computed tomography scan, esophagogastroduodenoscopy and colonoscopy.

The applied radiation techniques express historical technological developments from opposing fields (used in 98.2% of those participating in the first study) to three-dimensional conformal RT (used in 77.7% of those in the second study and 98.0% of those in the third (DSGL 01/2003) study; Table 1). One patient in the third study was already treated with intensity-modulated RT. The dose of normofractionated radiation delivered to each tumor was $40\text{ Gy} \pm 10\%$ except for one patient in the first study who received an underdosage of 15%. The adjuvant radiation dose in extended field was $30\text{ Gy} \pm 10\%$. In the first study the 14 patients with stage II disease (4.8% of the entire cohort) were treated with RT after previous chemotherapy with six cycles of COP chemotherapy. Radiation field sizes in the three study designs are shown in Table 1. After RT, a complete response was detected in 288 (99.3%) patients. Two patients died before radiation therapy was completed:

1 due to a cardiac event and 1 due to progression and change towards aggressive lymphoma (first study; Table 2).

Within the total collective of 290 patients, long-term follow-up data from 179 patients could be obtained. In the remaining 111 patients follow-up data after radiation treatment could not be ascertained, even after intensive research by personally contacting hospital departments, further attending physicians, family doctors and population registration offices. In the three studies about the same proportion of patients was lost to follow-up (35, 41 and 36%, respectively) due to changes of residence, closure of medical practices (Table 3). There were no further deaths according to the relevant information provided by registration authorities. The patients with randomly occurring lost to follow-up at the end of treatment were not included in the survival analysis, whereas the other 179 patients are shown in the Kaplan–Meier graphs of OS, EFS and LSS with censoring at the latest timepoint with information available, as required by biostatistical recommendation. Of the follow-up patients 34/179 died, cause of death was not related to gMZL in 31/34 patients (Fig. 1). The 3 patients who died from gMZL-related causes were participants of the first study and had primary stage II gMZL. Of these, 2 died from distant recurrence (1 indolent, 1 aggressive relapse), and the other developed early progressive disease (under primary RT) that transformed to aggressive lymphoma. Death occurred during salvage chemotherapy. No deaths were associated with RT. Follow-up results and survival analysis for these 179 patients, including an estimate of the confidence interval, is shown in Table 3. Over the course of the three studies, 5- and 10-year OS rates and 5- and 10-year EFS rates increased. Follow-up ended in the third study after 10 years, but of the remaining two, the first showed a tendency to greater 15-year OS and 15-year EFS rates. The three studies did not differ in OS ($p=0.463$; Fig. 2a) or EFS ($p=0.387$; Fig. 2b) rates.

Because of the 3 gMZL-related deaths in the first study, LSS was reduced to 93.9% (95% CI 85.6–100.0%) for the 5-, 10-, and 15-year rates. In contrast, these rates remained at 100% during follow-up for the second and third studies. The three studies yielded significantly different LSS rates ($p=0.026$; Fig. 2c). Individually, a statistical abnormality was detected between the first and second studies ($p=0.044$), but not between the second and third studies ($p=0.072$). In the first study, LSS differentiation by stage showed that the 5-, 10-, and 15-year LSS rates for stage II were 80.8% (95% CI 56.89–100.0%), whereas for stage I, it remained at 100% throughout follow-up. In this evaluation, LSS rates were significantly different ($p=0.008$) between stages I and II (Fig. 2d).

Of all followed patients, 10 experienced relapse, of which 6 patients relapsed within the radiation field (in the stomach) initially, and 4 patients relapsed outside, respec-

Table 2 Patient characteristics and acute toxicity (CTC) among indolent gastric marginal zone lymphoma (gMZL) in all studies (*n* = 290)

		GIT 1992	GIT 1996	DSGL 01/2003	Total
<i>Patients with indolent gMZL</i>		<i>n</i> = 57	<i>n</i> = 130	<i>n</i> = 103	<i>n</i> = 290
Age, median (range) in years		60 (24–76)	61 (29–84)	59 (26–80)	60 (24–84)
Sex					
Female		<i>n</i> = 28 (49.1%)	<i>n</i> = 63 (48.5%)	<i>n</i> = 50 (48.5%)	<i>n</i> = 141 (48.6%)
Male		<i>n</i> = 29 (50.9%)	<i>n</i> = 67 (51.5%)	<i>n</i> = 53 (51.5%)	<i>n</i> = 149 (51.4%)
<i>Ann-Arbor Stage</i>					
I		<i>n</i> = 43 (75.5%)	<i>n</i> = 87 (67.0%)	<i>n</i> = 67 (65.0%)	<i>n</i> = 197 (68.0%)
II					
II1		<i>n</i> = 8 (14.0%)	<i>n</i> = 28 (21.5%)	<i>n</i> = 25 (24.3%)	<i>n</i> = 61 (21.0%)
II2		<i>n</i> = 6 (10.5%)	<i>n</i> = 15 (11.5%)	<i>n</i> = 11 (10.7%)	<i>n</i> = 32 (11.0%)
Complete remission		<i>n</i> = 55 (96.5%) ^a	<i>n</i> = 130 (100%)	<i>n</i> = 103 (100%)	<i>n</i> = 288 (99.3%) ^a
<i>ECOG score</i>					
0		<i>n</i> = 25 (43.9%)	<i>n</i> = 77 (59.2%)	<i>n</i> = 68 (66.0%)	<i>n</i> = 170 (58.6%)
1		<i>n</i> = 30 (52.5%)	<i>n</i> = 43 (33.1%)	<i>n</i> = 31 (30.1%)	<i>n</i> = 104 (35.9%)
2		<i>n</i> = 2 (3.6%)	<i>n</i> = 10 (7.7%)	<i>n</i> = 4 (3.9%)	<i>n</i> = 16 (5.5%)
<i>Acute toxicity (CTC)^b</i>					
Drop in hemoglobin	0	<i>n</i> = 42 (73.7%)	<i>n</i> = 112 (86.2%)	<i>n</i> = 91 (88.3%)	<i>n</i> = 245 (84.5%)
	1–2	<i>n</i> = 10 (17.5%)	<i>n</i> = 18 (13.8%)	<i>n</i> = 11 (10.7%)	<i>n</i> = 39 (13.4%)
	3–4	<i>n</i> = 2 (3.5%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 2 (0.7%)
Leukocytopenia	0	<i>n</i> = 15 (26.3%)	<i>n</i> = 56 (43.1%)	<i>n</i> = 74 (71.8%)	<i>n</i> = 145 (50.0%)
	1–2	<i>n</i> = 33 (57.9%)	<i>n</i> = 68 (52.3%)	<i>n</i> = 24 (23.3%)	<i>n</i> = 125 (43.1%)
	3–4	<i>n</i> = 6 (10.5%)	<i>n</i> = 6 (4.6%)	<i>n</i> = 4 (3.9%)	<i>n</i> = 16 (5.5%)
Thrombocytopenia	0	<i>n</i> = 34 (59.6%)	<i>n</i> = 95 (73.1%)	<i>n</i> = 89 (86.4%)	<i>n</i> = 218 (75.2%)
	1–2	<i>n</i> = 19 (33.3%)	<i>n</i> = 30 (23.1%)	<i>n</i> = 13 (12.6%)	<i>n</i> = 62 (21.4%)
	3–4	<i>n</i> = 1 (1.8%)	<i>n</i> = 5 (3.8%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 6 (2.0%)
Elevated bilirubin	0	<i>n</i> = 52 (91.2%)	<i>n</i> = 123 (94.6%)	<i>n</i> = 99 (96.1%)	<i>n</i> = 274 (94.5%)
	1–2	<i>n</i> = 2 (3.5%)	<i>n</i> = 7 (5.4%)	<i>n</i> = 3 (2.9%)	<i>n</i> = 12 (4.1%)
	3–4	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)
Elevated transaminases	0	<i>n</i> = 48 (84.2%)	<i>n</i> = 122 (93.8%)	<i>n</i> = 97 (94.1%)	<i>n</i> = 267 (92.1%)
	1–2	<i>n</i> = 6 (10.5%)	<i>n</i> = 7 (5.4%)	<i>n</i> = 5 (4.9%)	<i>n</i> = 18 (6.2%)
	3–4	<i>n</i> = 0 (0.0%)	<i>n</i> = 1 (0.8%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 1 (0.3%)
Loss of appetite	0	<i>n</i> = 26 (45.6%)	<i>n</i> = 53 (40.8%)	<i>n</i> = 49 (47.6%)	<i>n</i> = 128 (44.1%)
	1–2	<i>n</i> = 24 (42.1%)	<i>n</i> = 69 (53.1%)	<i>n</i> = 48 (46.5%)	<i>n</i> = 141 (48.6%)
	3–4	<i>n</i> = 4 (7.0%)	<i>n</i> = 8 (6.1%)	<i>n</i> = 5 (4.9%)	<i>n</i> = 17 (5.9%)
Weight loss	0	<i>n</i> = 32 (56.1%)	<i>n</i> = 64 (49.2%)	<i>n</i> = 57 (55.3%)	<i>n</i> = 153 (52.8%)
	1–2	<i>n</i> = 21 (36.8%)	<i>n</i> = 60 (46.2%)	<i>n</i> = 44 (42.7%)	<i>n</i> = 125 (43.0%)
	3–4	<i>n</i> = 1 (1.8%)	<i>n</i> = 6 (4.6%)	<i>n</i> = 1 (1.0%)	<i>n</i> = 8 (2.8%)
Nausea	0	<i>n</i> = 20 (35.0%)	<i>n</i> = 30 (23.9%)	<i>n</i> = 34 (33.0%)	<i>n</i> = 84 (29.3%)
	1–2	<i>n</i> = 22 (38.6%)	<i>n</i> = 67 (51.5%)	<i>n</i> = 50 (48.5%)	<i>n</i> = 139 (47.9%)
	3–4	<i>n</i> = 12 (21.1%)	<i>n</i> = 33 (24.6%)	<i>n</i> = 18 (17.5%)	<i>n</i> = 63 (21.4%)
Diarrhea	0	<i>n</i> = 27 (47.4%)	<i>n</i> = 83 (63.8%)	<i>n</i> = 83 (80.6%)	<i>n</i> = 193 (66.6%)
	1–2	<i>n</i> = 11 (19.3%)	<i>n</i> = 37 (28.5%)	<i>n</i> = 17 (16.5%)	<i>n</i> = 65 (22.4%)
	3–4	<i>n</i> = 16 (28.0%)	<i>n</i> = 10 (7.7%)	<i>n</i> = 2 (1.9%)	<i>n</i> = 28 (9.6%)
Constipation	0	<i>n</i> = 52 (91.1%)	<i>n</i> = 123 (94.7%)	<i>n</i> = 94 (91.2%)	<i>n</i> = 269 (92.7%)
	1–2	<i>n</i> = 1 (1.8%)	<i>n</i> = 5 (3.8%)	<i>n</i> = 7 (6.8%)	<i>n</i> = 13 (4.5%)
	3–4	<i>n</i> = 1 (1.8%)	<i>n</i> = 2 (1.5%)	<i>n</i> = 1 (1.0%)	<i>n</i> = 4 (1.4%)

Table 2 (Continued)

		GIT 1992	GIT 1996	DSGL 01/2003	Total
Neurotoxicity	0	<i>n</i> = 53 (92.9%)	<i>n</i> = 130 (100%)	<i>n</i> = 101 (98.0%)	<i>n</i> = 284 (97.9%)
	1–2	<i>n</i> = 1 (1.8%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 1 (1.0%)	<i>n</i> = 2 (0.7%)
	3–4	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)	<i>n</i> = 0 (0.0%)

ECOG Eastern Cooperative Oncology Group, CTC Common Toxicity Criteria

Given are the numbers available with missing data being the difference between total numbers and given numbers

^a*n* = 2 patients died in the first study during RT, both not achieving CR (1 nontherapy-associated cardiac event, 1 progression as aggressive lymphoma receiving chemotherapy)

^bAcute toxicity (CTC), missing patients: GIT 1992 *n* = 3 (5.3%), GIT 1996 *n* = 0 (0.0%), DSGL 01/2003 *n* = 1 (1.0%), in total *n* = 4 (1.4%) of whom: 2 patients received only half of their planned radiation doses (1 died during primary therapy of a nontherapy-associated cardiac event, 1 other died after progression as aggressive lymphoma during primary therapy receiving chemotherapy); 2 other patients had incomplete documentation forms and the responsible radiotherapeutic institutions had no further information

tively (Table 4). Five out of the 10 relapsing patients, and 3 out of the 6 local relapses, belonged to the first study. During the course of the 3 studies, the total recurrence rate fell from 13.5 to 3.0%, and the local recurrence rate from 8.1 to 1.5%, respectively. On further follow-up, 3 developed a second relapse (2 distant, 1 local), and of those, 1 suffered a third relapse (distant). In total, 14 recurrence events were recorded.

Investigation revealed that the primary RT among patients with recurrence included a significant protocol violation (underdosage by 15% or inadequate RT field size) in 2 patients, 1 who developed local relapse and 1 who

developed distant relapse. Of those who developed more than one relapse, an indolent lymphoma had formed as the first relapse. In 2 of these 3, an indolent lymphoma again formed as a second relapse. The other developed an aggressive lymphoma in both the second and third relapses.

Of the 14 recurrence events, 11 occurred within the first five years, and 3 occurred much later (13.8, 14.5 and 18.2 years after the beginning of primary RT). Salvage therapy after the first relapse was successful, resulting in complete remission. Of the patients with a second relapse, 1 died from that event (indolent lymphoma in the multilocal craniofacial region and mediastinum), 1 again achieved continuing


**Fig. 1** Causes of death in *n* = 34 patients

Table 3 Follow-up results/events and long-term impairment of organ function (LENT SOMA) among indolent gastric marginal zone lymphoma (gMZL) in all studies ($n = 179$)

	GIT 1992	GIT 1996	DSGL 01/2003	Total
Follow-up patients with gMZL (of total)	$n = 37$ (64.9%)	$n = 76$ (58.6%)	$n = 66$ (64.1%)	$n = 179$ (61.7%)
Median observation time in years (months)	13.0 (156)	8.2 (98.5)	4.7 (56)	6.4 (77)
Events (progression/relapse/death)	$n = 13$ (35.1%) ^a	$n = 21$ (27.6%) ^b	$n = 7$ (10.5%) ^c	$n = 41$ (22.9%)
<i>Progression</i>	$n = 1$ (2.7%)	$n = 0$ (0.0%)	$n = 0$ (0.0%)	$n = 1$ (0.6%)
<i>Relapse in total</i>	$n = 5$ (13.5%)	$n = 3$ (3.9%)	$n = 2$ (3.0%)	$n = 10$ (5.6%)
Local	$n = 2$ (5.4%)	$n = 2$ (2.6%)	$n = 1$ (1.5%)	$n = 5$ (2.8%)
Distant	$n = 2$ (5.4%)	$n = 1$ (1.3%)	$n = 1$ (1.5%)	$n = 4$ (2.2%)
Local and distant	$n = 1$ (2.7%)	$n = 0$ (0.0%)	$n = 0$ (0.0%)	$n = 1$ (0.6%)
Early relapse	$n = 2$ (5.4%)	$n = 0$ (0.0%)	$n = 1$ (1.5%)	$n = 3$ (1.7%)
Late relapse	$n = 3$ (8.1%)	$n = 3$ (3.9%)	$n = 1$ (1.5%)	$n = 7$ (3.9%)
<i>Death in total</i>	$n = 11$ (29.7%)	$n = 18$ (23.7%)	$n = 5$ (7.6%)	$n = 34$ (19.0%)
Related to treatment	$n = 0$ (0.0%)	$n = 0$ (0.0%)	$n = 0$ (0.0%)	$n = 0$ (0.0%)
<i>DOD</i>	$n = 3$ (8.1%)	$n = 0$ (0.0%)	$n = 0$ (0.0%)	$n = 3$ (1.7%)
Other diseases	$n = 8$ (21.6%)	$n = 17$ (22.4%)	$n = 3$ (4.6%)	$n = 28$ (15.6%)
Not lymphoma associated	$n = 0$ (0.0%)	$n = 1$ (1.3%)	$n = 2$ (3.0%)	$n = 3$ (1.7%)
Overall survival (with 95% CI)				
Five-year	85.8% (74.2–97.3)	87.2% (79.4–95.0)	92.7% (85.6–99.8)	–
Ten-year	75.2% (60.1–90.3)	73.2% (61.4–85.0)	87.9% (76.5–99.2)	–
Fifteen-year	71.0% (54.5–87.5)	66.4% (52.5–80.3)	–	–
Event-free survival (with 95% CI)				
Five-year	74.4% (60.0–88.9)	84.4% (76.0–92.8)	89.5% (81.4–97.5)	–
Ten-year	66.9% (50.6–83.2)	70.9% (59.1–82.6)	84.5% (72.3–96.7)	–
Fifteen-year	62.8% (45.6–80.1)	58.5% (41.8–75.2)	–	–
Lymphoma-specific survival (with 95% CI)				
Five-year	93.9% (85.6–100)	100%	100%	–
Ten-year	93.9%	100%	100%	–
Fifteen-year	93.9%	100%	–	–
Impaired Organ function (LENTSOMA)^d				
Liver				
0	$n = 33$ (89.2%)	$n = 72$ (94.7%)	$n = 64$ (97.0%)	$n = 169$ (94.4%)
1–2	$n = 1$ (2.7%)	$n = 3$ (4.0%)	$n = 1$ (1.5%)	$n = 5$ (2.8%)
Kidney				
0	$n = 32$ (86.5%)	$n = 69$ (90.8%)	$n = 63$ (95.5%)	$n = 164$ (91.6%)
1–2	$n = 2$ (5.4%)	$n = 6$ (7.9%)	$n = 2$ (3.0%)	$n = 10$ (5.6%)
Bladder				
0	$n = 33$ (89.2%)	$n = 74$ (97.4%)	$n = 65$ (100.0%)	$n = 172$ (96.1%)
1–2	$n = 1$ (2.7%)	$n = 1$ (1.3%)	$n = 0$ (0.0%)	$n = 2$ (1.1%)
Stomach and bowel				
0	$n = 32$ (86.5%)	$n = 72$ (94.7%)	$n = 63$ (95.5%)	$n = 167$ (93.2%)
1–2	$n = 2$ (5.4%)	$n = 3$ (4.0%)	$n = 2$ (3.0%)	$n = 7$ (3.9%)

DOD died of disease, *early relapse* relapse within the first year after start of treatment, *late relapse* relapse after the first year of treatment, *CI* confidence interval, *LENT SOMA* Late Effects on Normal Tissue Subjective Objective Management

^a $n = 13$ patients developed events within the first study, of whom $n = 2$ patients died from relapse and $n = 1$ died from progress (see $n = 3$ patients *DOD* indicated in *italics*, in the first study)

^b $n = 21$ patients developed events within the second study, of whom no patient died from relapse or progress

^c $n = 7$ patients developed events within the third study, of whom no patient died from relapse or progress

^dImpaired organ function (LENT SOMA), missing patients: GIT 1992 $n = 3$ (8.1%), GIT 1996 $n = 1$ (1.3%), DSGL 01/2003 $n = 1$ (1.5%), in total $n = 5$ (2.8%) died during the first 90 days after the start of radiation therapy, therefore by definition no long-term impairment of organ function could be observed

Fig. 2 a Overall survival (OS), $p = 0.463$, Number of deaths $n = 11$ (GIT 1992), $n = 18$ (GIT 1996), $n = 5$ (DSGL 01/2003). Median follow-up time 13.0 years (GIT 1992), 8.2 years (GIT 1996), 4.7 years (DSGL 01/2003). **b** Event-free survival (EFS), $p = 0.387$, Number of events $n = 13$ (GIT 1992), $n = 21$ (GIT 1996), $n = 7$ (DSGL 01/2003). Median follow-up time 13.0 years (GIT 1992), 8.2 years (GIT 1996), 4.7 years (DSGL 01/2003)





Fig. 2 (continued) **c** Lymphoma-specific survival (LSS), $p = 0.026$, Number of deaths related to lymphoma or therapy $n = 3$ (GIT 1992), $n = 0$ (GIT 1996), $n = 0$ (DSGL 01/2003), Median follow-up time 13.0 years (GIT 1992), 8.2 years (GIT 1996), 4.7 years (DSGL 01/2003). **d** Lymphoma-specific survival (LSS) study GIT 1992, stage-dependent (I and II), $p = 0.008$, Number of lymphoma-specific deaths $n = 3$, Median follow-up time 13.0 years



complete response with *H. pylori* eradication (indolent lymphoma in the stomach), and 1 was salvaged successfully with multimodal surgery–chemotherapy–RT for 3.7 years until the third relapse (aggressive lymphoma in the lung). This event caused death.

The two relapse patients who died of lymphoma were part of the first study. A third relapsing patient, also part

of the first study, died during follow-up (6.9 years after the beginning of primary RT), but unlike the others, death was caused by metastases of a previous non-small cell lung cancer.

Table 4 Relapse characteristics (*n* = 10)

		GIT 1992	GIT 1996	DSGL 01/2003	Total
<i>Follow-up patients with relapses</i>		<i>n</i> = 5 (13.5%)	<i>n</i> = 3 (3.9%)	<i>n</i> = 2 (3.0%)	<i>n</i> = 10 (5.6%)
<i>Sex</i>					
Female		<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 2	<i>n</i> = 4
Male		<i>n</i> = 3	<i>n</i> = 3	<i>n</i> = 0	<i>n</i> = 6
<i>Age in years</i>		30, 33, 35, 69, 71	52, 65, 72	71, 45	Median: 58.5 Range (30–72)
<i>Ann-Arbor Stage</i>					
I		<i>n</i> = 2	<i>n</i> = 3	<i>n</i> = 1	<i>n</i> = 6
II					
II1		<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 2
II2		<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 2
<i>ECOG</i>					
0		<i>n</i> = 3	<i>n</i> = 3	<i>n</i> = 0	<i>n</i> = 6
1		<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 3
2		<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 1
<i>RT protocol</i>					
<i>Deviation^a</i>	No	<i>n</i> = 0	<i>n</i> = 2	<i>n</i> = 2	<i>n</i> = 4
	Yes	<i>n</i> = 3	<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 4
<i>Violation^b</i>	Yes	<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 2
<i>Relapse location</i>					
Local		<i>n</i> = 2	<i>n</i> = 2	<i>n</i> = 1	<i>n</i> = 5
Distant		<i>n</i> = 2	<i>n</i> = 1	<i>n</i> = 1	<i>n</i> = 4
Local + distant ^c		<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1
<i>First relapse histology</i>					
Indolent		<i>n</i> = 4	<i>n</i> = 3	<i>n</i> = 1	<i>n</i> = 8
Aggressive		<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 1
Indolent-aggressive		<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1
<i>First relapse interval^d in months</i>		7, 7, 24, 36, 42	19, 20, 166	3, 15	Median: 19.5 Range (3–166)
<i>First relapse timing^e</i>					
Early		<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 3
Late		<i>n</i> = 3	<i>n</i> = 3	<i>n</i> = 1	<i>n</i> = 7
<i>First salvage therapy</i>					
Surgery		<i>n</i> = 1	<i>n</i> = 2	<i>n</i> = 0	<i>n</i> = 3
Eradication		<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 1
Radiotherapy		<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1
Immunotherapy		<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 1
Multimodal		<i>n</i> = 3	<i>n</i> = 0	<i>n</i> = 1	<i>n</i> = 4
<i>First salvage CR^f</i>					
Persistent		<i>n</i> = 3	<i>n</i> = 2	<i>n</i> = 2	<i>n</i> = 7
Temporary		<i>n</i> = 2	<i>n</i> = 1	<i>n</i> = 0	<i>n</i> = 3
<i>Re-relapse interval^g in months</i>		11, 150	36	–	Median: 36 Range (11–150)

Acute toxicities

Of the 290 patients treated with RT, RT-related *acute toxicities*, using the Common Terminology Criteria for Adverse Events, Common Toxicity Criteria (CTC) (Version 4.03) reporting system [15], could be obtained in 286. Half the

prescribed radiation dose was administered to 2 patients, of whom 1 died due to a cardiac event, and 1 died after a change in therapy after tumor progression and a conversion to aggressive lymphoma. The remaining 2 patients could not be evaluated for toxicity because data are not available (Table 2).

Table 4 (Continued)

	GIT 1992	GIT 1996	DSGL 01/2003	Total
<i>Re-salvage therapy</i>				
Radiotherapy	<i>n</i> = 1	–	–	<i>n</i> = 1
Multimodal	<i>n</i> = 1	<i>n</i> = 1	–	<i>n</i> = 2
<i>Second salvage CR^h</i>				
Persistent	<i>n</i> = 0	<i>n</i> = 1	–	<i>n</i> = 1
Temporary	<i>n</i> = 1	<i>n</i> = 0	–	<i>n</i> = 1
No	<i>n</i> = 1	<i>n</i> = 0	–	<i>n</i> = 1
<i>Death</i>				
No	<i>n</i> = 2	<i>n</i> = 3	<i>n</i> = 2	<i>n</i> = 7
Yes	<i>n</i> = 3	<i>n</i> = 0	<i>n</i> = 0	<i>n</i> = 3
<i>DOD</i>				
No	<i>n</i> = 1	–	–	<i>n</i> = 1
Yes	<i>n</i> = 2	–	–	<i>n</i> = 2

RT radiation therapy, DOD died of disease, CR complete remission, ECOG Eastern Cooperative Oncology Group

^aProtocol deviation means dose deviation >5 and <10%

^bProtocol violation means dose deviation ≥10% or false radiation field size

^cLocal at first relapse and distant at second/third relapse

^dRelapse-interval between start of RT and first relapse

^eRelapse timing early = within the first year after start of treatment/late = after the first year after start of treatment

^fFirst salvage CR = de novo complete remission after first salvage therapy

^gRe-relapse-interval = between first salvage therapy and second relapse

^hSecond salvage CR = de novo complete remission after second salvage therapy

Laboratory blood values

Acute *hematotoxicity* grades 3 and 4 decreased with each successive study. In the entire cohort, the most frequent hematotoxic side effect of any grade was related to leukocytopenia. Reductions in the relative frequencies of anemia ($p = 0.005$), leukocytopenia ($p = 0.001$) and thrombocytopenia ($p = 0.001$) of any grade were statistically significant between studies. Acute *hepatotoxicity* grades 3 and 4 related to transaminases occurred rarely in the second study (1/130 patients, 0.8%). The trends towards lower relative frequencies of elevated bilirubin ($p = 0.057$) and the transaminases AST and ALT ($p = 0.062$), regardless of grade, were not statistically significant between the three cohorts.

Clinical adverse reactions

Across all studies, the most frequent gastrointestinal side effects of any grade were nausea followed by loss of appetite, weight loss, and diarrhea; constipation was rare. *Gastrointestinal acute toxicities* grades 3 and 4 decreased clearly across the three studies, being 59.6% (34/57), 45.4% (59/130), and 26.2% (27/103), respectively. Reduction in the relative frequency of diarrhea ($p = 0.001$) was significant. Development of the relative frequency of nausea with an intermittent increase between the first and the second study, and a decrease (in particular of grades 3 and 4) towards the third study were statistically significant

($p = 0.037$). *Neurologic acute toxicity* grades 3 and 4 were not evident.

Chronic toxicities

Of the 179 followed patients, *chronic toxicities*, according to the LENT SOMA (Late Effects on Normal Tissue, Subjective Objective Management) scoring system [16], were obtainable in 174 patients (Table 3). The trends towards lower relative frequencies of *impaired organ functions* of the liver ($p = 0.332$), kidneys ($p = 0.367$), gastrointestinal tract ($p = 0.362$) and urinary bladder ($p = 0.247$) of any grade were not statistically significant between the studies. Chronic RT-associated side effects in organ functions were limited to grades 1 or 2 and were rare in the followed patients across all three studies.

Of the entire cohort, during the maximum 22-year follow-up period, 4 patients developed second malignancies outside the radiation field. These occurred from 2.8 to 13.1 years after RT ($n = 2$ for bronchial carcinoma, $n = 1$ for Hodgkin's lymphoma, $n = 1$ for glioblastoma). All received specific oncologic treatment (chemotherapy in Hodgkin's lymphoma, standard multimodal treatment for the glioblastoma and RT for the others), but all experienced progression and died from their second malignancies within 2 to 7 months.

Discussion

The three prospective studies aimed at optimizing the radiation field size in gMZL. To our knowledge, this is the largest cohort of patients with early stage gMZL treated conservatively with curative radiation therapy. The three studies subgroups with median follow-ups of 13.0, 8.2 and 4.7 years allow an extensive analysis of the course of this rare disease. Stage-adapted radiation therapy of indolent gastric lymphoma has been established worldwide as a curative primary therapy because of the option for stomach-maintenance and the success in lymphoma regression [11–13, 17, 18]. After locoregional radiation therapy in this patient collective, of which 4.8% received previous chemotherapy, the outcome is excellent with an exceptionally high complete response rate of 99.3% and low disease-specific death rate of 3 patients. Progressive disease occurred in 1 patient, but relapse occurred in 5.6% (10/179) of the followed patients. Local relapse was more frequent than distant (1.5:1), similar to previous reports [19, 20]. The total and in particular the local recurrence rate being at their highest in the first study might be due to the further development of radiation technique towards a predominantly three-dimensional conformal RT within the second and third study. Local relapses were always non-transformed MZL, distant relapses were equally transformed or non-transformed lymphoma. All first recurrences were successfully salvaged, most commonly resulting in continuing *de novo* complete remission, and second relapse occurred in 3 patients, again after long disease-free intervals. Disease-specific survival remains high due to effective salvage therapies and a small proportion of progression to further advanced disease.

In this collective the stage of gMZL was identified as a significant factor associated with disease-specific survival, given that stage II patients were the only ones who died of disease. Lymphoma stage was a strong prognostic factor, as it was in other studies [21].

Radiation therapy as definitive treatment approach in gMZL is well-tolerated, no RT-associated deaths occurred in the entire cohort. Relevant acute toxicity was related to hematotoxicity and gastrointestinal toxicity and significantly improved with RT field reduction. Moderate chronic RT-associated side effects rarely appeared and tended to occur with lower relative frequencies in the course of the successive studies. The impairment of organ function was reduced as the RT field size decreased. Three deaths were caused by metastases from previous cancers, and four deaths were caused by out-of-field second malignancies that developed during follow-up.

This cohort is similarly composed and shows acute and chronic adverse effects that are consistent with that found in the literature [9, 18, 20, 22–24]. Results confirm that excellent outcomes result when early stage gMZL is treated with

RT, as reported in the literature. In the final study (DSGL 01/2003), the 5-year OS, EFS, and LSS are comparable, and the 10-year OS is more favorable than reported for other studies of gastric lymphoma. Reportedly, the 5-year OS is 90.3–94%, 10-year OS is 70.0–87%, 5-year EFS is 74.0–89.0%, 10-year EFS is 57.0–92.0%, 5-year LSS is 99.0–100%, 10-year LSS is 98% [9, 19, 20, 22, 24]. In a group of 244 patients with stage I or II extranodal MZL with heterogeneous disease sites (about 50% in the stomach), initially treated with RT alone, the reported risk of relapse for the stomach was relatively low compared to other sites; the risk of relapse after RT was significantly lower compared with other strategies [25].

The rate of transformation to aggressive lymphoma in our followed subgroup is 1.7%, relatively low compared with the literature [9, 19, 22]. Our follow-up results show that relapse occurs primarily within 5 years, and it also confirms that relapse can be late, given 3 relapse events occurred between 13.8 and 18.2 years respectively after the beginning of RT, emphasizing the importance of lifelong follow-up [19, 26]. Over the past two decades considerable interest has focused on the prescribed RT dose in indolent non-Hodgkin lymphomas in different anatomical sites. The clinical trials in the United States, Canada and the United Kingdom including smaller sample sizes in varied locations have already been conducted with very effective lower radiation doses of at median 24 or 30 Gy [7, 9, 19, 25, 27], whereas in Australia, Germany and the Netherlands large studies particularly in gastric indolent lymphoma were continued with highly effective doses of a median 40 Gy [13, 20, 28]. The use of very low-dose radiotherapy in indolent lymphoma has also been studied recently [27, 29] with limited but very encouraging tumor response rates. With its excellent lymphoma response rate, our study revealed no pattern between applied RT dose and in-field failure in gMZL.

The primary limitation of this study is the proportion (38%) of patients randomly lost to follow-up directly after radiation treatment. This is associated with a long follow-up period, particularly in the first study (GIT 1992). The varied follow-up periods across the three studies were incorporated in survival analyses, which must be considered when comparing results. The strengths of this analysis include the large cohort of gMZL patients treated with definitive radiation therapy, the centrally confirmed diagnoses by experienced hematopathologists, the standardized radiation therapy approach with follow-up examinations, and the length of observation time. The large sample size and length of follow-up period provide detailed information about the efficacy and long-term outcome of historically considerably reduced RT fields in gMZL.

Conclusion

Early stage gMZL can be treated successfully with stage-adapted small-volume RT, which results in minimal toxicity and excellent long-term lymphoma control. Despite the low yet longer-term risk of disease recurrence, the natural course is predominantly indolent, and the OS of gMZL remains high after salvage therapy. These results are encouraging for further decreases in modern radiation treatment of gMZL, as application of the involved site radiation therapy (ISRT), recommended by the International Lymphoma Radiation Oncology Group, and evaluation of the optimal lower end of radiation dose (potentially below the actual international standard dose of 30 Gy).

Acknowledgements We thank all patients, treating physicians, investigators and participants, who provided ongoing support for these trials. This work was supported by 78 radiotherapeutic institutions in Germany, listed in the appendix. The biostatistical assistance of Dr. Rene Schmidt, Institute of Biostatistics and Clinical Research University of Münster, is gratefully acknowledged.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical guidelines

Conflict of interest G. Reinartz, R.P. Pyra, G. Lenz, R. Liersch, G. Stüben, O. Micke, K. Willborn, C.F. Hess, A. Probst, R. Jany, J. Schultze, C. Rübe, C. Hirt, W. Fischbach, M. Bentz, S. Daum, C. Pott, M. Tiemann, P. Möller, A. Neubauer, M. Wilhelm, N. Willich, W.E. Berdel and H.T. Eich declare that they have no competing interests. R. Fietkau reports grants, personal fees and non-financial support from Merck Serono, personal fees and non-financial support from Fresenius Kabi, personal fees and non-financial support from Novocure, grants, personal fees and non-financial support from MSD, grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Brainlab, personal fees and non-financial support from Sennewald GmbH, personal fees and non-financial support from Bristol-Myers Squibb, outside the submitted work.

Ethical standards The trials were conducted in accordance with the Declaration of Helsinki on Ethical Principles for Medical Research after approval of the Ethical Board of the physicians' chamber of Westfalia-Lippe and the Westfalian Wilhelms-University of Münster. The studies were reviewed by the local Ethical Committees (institutional review boards) of the involved trials sites.

Appendix

In addition to the authors listed on the manuscript, the supporting institutions were as follows: Aalen Radiotherapy, Aschaffenburg Radiotherapy Practice, Augsburg Radiotherapy Joint Practice, Aurich Norden Medical Care Center, Bad Saarow Helios Hospital, Bocholt Radiotherapy Practice, Bochum Catholic Hospital, Bonn University Hospital, Braunschweig Municipal Hospital, Bremen-Mitte Hospital, Celle General Hospital, Dessau Municipal Hospital,

Dortmund Knappschafts-Hospital, Düsseldorf University Hospital, Düsseldorf Marienhospital, Essen University Hospital, Essen Alfred Krupp Hospital, Essen Radiotherapy Practice, Flensburg St. Franziskus Hospital, Frankfurt Northwest Hospital, Fulda Hospital, Gießen Wilhelm Conrad Röntgen Hospital, Görlitz Radiotherapy Practice, Hagen General Hospital, Halle/Saale University Hospital, Hamburg St. Georg Radiotherapy Practice, Hamburg Altona Radiotherapy Practice, Hanau Hospital, Hannover Medical University, Hannover Diakovere Friederikenstift Hospital, Heidenheim Hospital, Herford Hospital, Jena University Hospital, Karlsruhe Vincentius Hospital, Kassel Municipal Hospital, Kassel Radiotherapy Practice, Kempten Hospital, Koblenz Radiological Institute, Köln University Hospital, Krefeld Helios Hospital, Lippstadt Dreifaltigkeits-Hospital, Lübeck University Hospital, Ludwigshafen Klinikum Ludwigshafen, Magdeburg University Hospital, Mannheim University Hospital, Minden Hospital, Mönchengladbach Maria Hilf Hospital, Mühlheim a.d. Ruhr Protestant Hospital, München Klinikum rechts d. Isar University Hospital, Neubrandenburg Dietrich Bonhoeffer Hospital, Neuss Lukas-Hospital, Nordhorn Radiotherapy Practice, Osnabrück Paracelsus Hospital, Osnabrück Radiotherapy Practice, Ostfildern Medius Hospital, Paderborn Brüderkrankenhaus St. Josef Hospital, Pinneberg Radiotherapy Joint Practice, Recklinghausen Knappschafts-Hospital, Rendsburg District Hospital, Rostock University Hospital, Schwerin Helios Hospital, Siegen St. Marien Hospital, Stuttgart Marienhospital, Trier Mutterhaus der Borromäerinnen Hospital, Vechta Medical Care Center, Wuppertal Radiotherapy Practice.

References

1. Aebbersold DM, Vetterli D, Greiner RH (2004) Therapieplanung: 3D-konformierende Bestrahlung und intensitätsmodulierte Strahlentherapie. In: Krukemeyer G, Wagner W (eds) Strahlentherapie. Ein Leitfaden für Praktiker. De Gruyter, Berlin New York, pp 175–189
2. Della Bianca C, Hunt M, Fuhang E, Wu E, Yahalom J (2005) Radiation treatment planning techniques for lymphoma of the stomach. *Int J Radiat Oncol Biol Phys* 62(3):745–751. <https://doi.org/10.1016/j.ijrobp.2004.10.025>
3. Gregoire V, Mackie TR (2011) State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). *Cancer* 15(6–7):555–559. <https://doi.org/10.1016/j.canrad.2011.04.003>
4. Inaba K, Okamoto H, Wakita A, Nakamura S, Kobayashi K, Harada K et al (2014) Radiotherapy for gastric lymphoma: a planning study of 3D-conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. *J Radiat Res* 66(6):1141–1145. <https://doi.org/10.1093/jrr/tru052>
5. Reinartz G, Kardels B, Koch P, Willich N (1999) Analysis of failures after whole abdominal irradiation in gastrointestinal lymphomas. Is prophylactic irradiation of inguinal lymph nodes required? German Multicenter Study Group on GI-NHL, University of Muenster. *Strahlenther Onkol* 175(12):601–605

6. Reinartz G, Haverkamp U, Wullenkord R, Lechrich P, Kriz J, Büther F et al (2016) 4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma: determination of intra- and interfractional gastric motion. *Strahlenther Onkol* 192(5):322–332. <https://doi.org/10.1007/s00066-016-0949-0>
7. Schechter NR, Portlock CS, Yahalom J (1998) Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. *J Clin Oncol* 16:1916–1921. <https://doi.org/10.1200/JCO.1998.16.5.1916>
8. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R et al (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 92(1):11–31. <https://doi.org/10.1016/j.ijrobp.2015.01.009>
9. Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A et al (2010) Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. *Cancer* 116(16):3815–3824. <https://doi.org/10.1002/cncr.25226>
10. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M (2013) Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 24(6):144–148. <https://doi.org/10.1093/annonc/mdt343>
11. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W et al (2001) Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. *J Clin Oncol* 19(18):3861–3873. <https://doi.org/10.1200/JCO.2001.19.18.3861>
12. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W et al (2001) Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma. Results of the prospective German multicenter study GIT NHL 01/92. *J Clin Oncol* 19:3874–3883. <https://doi.org/10.1200/JCO.2001.19.18.3874>
13. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J et al (2005) Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). *J Clin Oncol* 23(28):7050–7059. <https://doi.org/10.1200/JCO.2005.04.031>
14. Hübel K, Thomas RK, Diehl V (2005) Morbus Hodgkin. In: Hiddemann W, Dreyling M, Stein H (eds) *Lymphome. Neue Erkenntnisse und Therapiestrategien*, 1st edn. Thieme, Stuttgart, pp 52–69
15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 13(3):176–181. [https://doi.org/10.1016/S1053-4296\(03\)00031-6](https://doi.org/10.1016/S1053-4296(03)00031-6)
16. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH (1995) RTOG Late Effects Working Group. Overview. Late effects of normal tissues (LENT) scoring system. *Int J Radiat Oncol Biol Phys* 31(5):1041–1042
17. Coiffier B, Salles G (1997) Does surgery belong to medical history for gastric lymphomas? *Ann Oncol* 8:419–421
18. Yoon SS, Coit DG, Portlock CS, Karpeh MS (2004) The diminishing role of surgery in the treatment of gastric lymphoma. *Ann Surg* 240:28–37
19. Teckie S, Qi S, Lovie S, Navarrett S, Hsu M, Nov A et al (2015) Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. *Int J Radiat Oncol Biol Phys* 92(1):130–137. <https://doi.org/10.1016/j.ijrobp.2015.01.040>
20. Wirth A, Gospodarowicz M, Aleman BMP, Bressel M, Ng A, Chao M et al (2013) Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-center, International Extranodal Lymphoma Group study. *Ann Oncol* 24:1344–1351. <https://doi.org/10.1093/annonc/mds623>
21. Wang YG, Zhao LY, Liu CQ, Pan SC, Chen XL, Liu K et al (2016) Clinical characteristics and prognostic factors of primary gastric lymphoma: a retrospective study with 165 cases. *Medicine* 95(31):e4250. <https://doi.org/10.1097/MD.00000000000004250>
22. Kim SW, Lim DH, Ahn YC, Kim WS, Kim SJ, Ko YH et al (2013) Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. *World J Gastroenterol* 19(36):6062–6068. <https://doi.org/10.3748/wjg.v19.i36.6062>
23. Maor MH, North LB, Cabanillas FF, Ames AL, Hess MA, Cox JD (1998) Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma. *Int J Radiat Oncol Biol Phys* 41:647–650
24. Nam TK, Ahn JS, Choi YD, Jeong JU, Kim YH, Yoon MS et al (2014) The role of radiotherapy in the treatment of gastric mucosa-associated lymphoid tissue lymphoma. *Cancer Res Treat* 46(1):33–40. <https://doi.org/10.4143/crt.2014.46.1.33>
25. Teckie S, Qi S, Chelius M, Lovie S, Hsu M, Nov A et al (2017) Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. *Ann Oncol* 28(5):1064–1069. <https://doi.org/10.1093/annonc/mdx025>
26. Raderer M, Streubel B, Woehrer S, Puspoeck A, Jaeger U, Formanek M et al (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. *Clin Cancer Res* 11:3349–3352. <https://doi.org/10.1158/1078-0432.CCR-04-2282>
27. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T et al (2011) Reduced dose radiotherapy for local control in Non-Hodgkin lymphoma: a randomised phase III trial. *Radiother Oncol* 100:86–92. <https://doi.org/10.1016/j.radonc.2011.05.013>
28. Vrieling C, de Jong D, Boot H, de Boer JP, Wegmann F, Aleman BM (2008) Long-term results of stomach-conserving therapy in gastric MALT lymphoma. *Radiother Oncol* 87(3):405–411. <https://doi.org/10.1016/j.radonc.2008.02.012>
29. Hoskin P, Kirkwood A, Popova B, Smith P, Robinson M, Gallop-Evans E et al (2014) 4Gy versus 24Gy radiotherapy for patients with indolent lymphoma (FORT): a randomized phase 3 non-inferiority trial. *Lancet Oncol* 15:457–463. [https://doi.org/10.1016/S1470-2045\(14\)70036-1](https://doi.org/10.1016/S1470-2045(14)70036-1)